Insomnia patients taking cannabis-based medical products reported better quality sleep after up to 18 months of treatment, according to a study published August 27 in the open-access journal PLOS Mental Health by Arushika Aggarwal from Imperial College London, U.K., and colleagues.

About one out of every three people has some trouble getting a good night’s rest, and 10 percent of adults meet the criteria for an insomnia disorder. But current treatments can be difficult to obtain, and the drugs approved for insomnia run the risk of dependence. To understand how cannabis-based medical products might affect insomnia symptoms, the authors of this study analyzed a set of 124 insomnia patients taking medical cannabis products. They examined the patient’s reports of their sleep quality, anxiety/depression, and quality of life changes between one and 18 months of treatment.

The patients reported improved sleep quality that lasted over the 18 months of treatment. They also showed significant improvements in anxiety/depression as well as reporting less pain. About nine percent of the patients reported adverse effects such as fatigue, insomnia, or dry mouth, but none of the side effects were life-threatening. While randomized controlled trials will be needed to prove that the products are safe and effective, the authors suggest that cannabis-based medical products could improve sleep quality in insomnia patients.

Co-author Dr. Simon Erridge, Research Director at Curaleaf Clinic, summarizes: “Over an 18-month period, our study showed that treatment for insomnia with cannabis-based medicinal products was associated with sustained improvements in subjective sleep quality and anxiety symptoms. These findings support the potential role of medical cannabis as a medical option where conventional treatments have proven ineffective, though further randomised trials are needed to confirm long-term efficacy.”

He adds: “Conducting this long-term study provided valuable real-world evidence on patient outcomes that go beyond what we typically see in short-term trials. It was particularly interesting to observe signs of potential tolerance over time, which highlights the importance of continued monitoring and individualized treatment plans.”



Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Explore More

Why religious groups are pushing for psychedelics as sacrament

Texas passed a landmark law in June 2025, supported by former Gov. Rick Perry, that allocates US$50 million to support research on ibogaine, one of the most powerful psychedelics, for

Kidney transplantation among those with HIV infections shown safe and effective, study suggests

It is just as safe and effective for people with HIV in need of kidney transplantation to get their organ from donors who are also HIV positive as it is

Medical Bills Can Be Vexing and Perplexing. Here’s This Year’s Best Advice for Patients.

A Texas boy’s second dose of the MMRV vaccine cost over $1,400. A Pennsylvania woman’s long-acting birth control cost more than $14,000. Treatment for a Florida Medicaid enrollee’s heart attack